PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 20250 citations

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

View Full Paper
NSNiccolò G. SantinNSNamrata SethiSBStefania Bellone

Key Points

  • Preclinical activity indicates that datopotamab deruxtecan effectively targets TROP2 in endometrial carcinoma types.
  • Flow cytometry analysis shows characteristic histograms of primary endometrial carcinoma cell lines used in the assessment.
  • The methodology involved examining primary EC cell lines to evaluate therapeutic responses to the antibody-drug conjugate.
  • These findings suggest potential clinical applications for Dato-DXd in treating poorly differentiated endometrial carcinomas.

Abstract

Supplemental Figure 1. Representative flow cytometry histograms of the primary EC cell lines used in this experiment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santin et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3031b076d99fa54924https://doi.org/10.1158/2767-9764.30102506
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  2. 2Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  3. 3Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  4. 4Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  5. 5Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025